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The 1000 Genomes Project and other “big data” studies have identified an unprecedented number of 
potential cancer biomarkers. However, as the number of potential biomarkers grows, sorting through 
them to identify the most useful predictors for both populations and individual patients becomes a 
substantial problem. In a recent paper published in BMC Medical Informatics and Decision Making, 
Drs. Xiaohong Li and Thomas L. Vaughan (Public Health and Human Biology Divisions), in 
collaboration with researchers at the University of Washington, developed a mathematical index 
called the naïve Ratio of Population Benefit (RPB), which takes into account both the benefits of 
biomarkers as screening tools as well as the potential adverse effects from using a biomarker 
inappropriately, as a framework to quantitatively assess the utility of biomarkers. 
Biomarkers are useful in several scenarios including the prediction of individuals in a population who 
will develop disease (risk prediction), identifying individuals with diseases that are currently 
asymptomatic (early detection), identifying pathways for therapeutic intervention (targeted 
prevention/therapy), and identifying risk factors that increase the possibility of disease (risk 
prevention). Conceptually, a given biomarker is likely to be more useful for some of these categories 
than others, so using published biomarkers clinically without a well-established framework for 
evaluation can lead to either underdiagnosis, missing true cases of cancer, or overdiagnosis, 
improperly diagnosing disease-free patients with cancer. Therefore, integrating both the potential 
risks of over- or underdiagnosis with the potential benefit is a critical step to translate these 
biomarkers from the bench to the bedside. 
  
To illustrate this point, Li, et al. demonstrate that traditional measures for biomarker efficacy, such as 
odds ratios, sensitivity, and specificity, may have different impacts depending on the situation in 
which they are applied. For example, a biomarker with low prevalence in the population will have 
very low sensitivity, a measure of the true positive rate of detection, even if the biomarker is very 
strongly associated with disease.  Therefore, even combining multiple low-frequency biomarkers into 
an assay may have limited utility for population level analyses such as risk prediction or early 
detection. Because false-positives and false-negatives are unavoidable, Li, et al. developed the 
naïve ratio of population benefit (RPB), a mathematical tool that considers the adverse effects of 
misclassification when evaluating the overall benefit of a given biomarker for population level 
April 21, 2014 SCIENCE SPOTLIGHT 
 
2 Volume 4, Issue 4 | Fred Hutchinson Cancer Research Center 
 
reduction of disease burden. In addition, the RPB index considers disease prevalence, a variable 
that is not generally taken into account by current methods for biomarker evaluation. 
Translating newly identified biomarkers into informative tools for epidemiological and clinical use is 
the next challenge for large-scale studies. Li, et al. propose a risk benefit approach to analyze the 
utility of these biomarkers for both preventive approaches and risk prediction/early intervention 
strategies. The current study provides an excellent framework for analyzing biomarkers at a single 
time point. "It is well known that disease development is a stochastic, dynamic process. The future 
work needs to incorporate time as a factor in this quantitative evaluation process," said Dr. Li.   
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Logogram of potential risk factor and biomarker categories (top), and the equation for the Ratio of 
Population Benefit (bottom). See the paper for definitions of the variables. 
